1. Cemiplimab significantly reduces recurrence in high-risk cSCC patients.
2. Disease-free survival at 24 months was 87% for cemiplimab vs 64% for placebo.
3. Serious adverse events occurred in 24% of cemiplimab patients.
4. The trial involved 415 patients across 107 sites in 16 countries.
5. Median follow-up of 24 months required for further data on overall survival.
6. Higher locoregional and distant recurrence rates were noted in placebo patients.

Source: New England Journal of Medicine